Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment for HER2-Positive Breast Cancer
Technology in Cancer Research & Treatment · 2026
DOI: 10.1177/15330338261446455 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, 2026. Verfasst von Anqi Shang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-S…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Molecular Targeted Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
HER2-positive breast cancer, characterized by overexpression of the human epidermal growth factor receptor 2 (HER2), accounts for approximately 15-20% of all breast cancers and is associated with aggressive tumor behavior and poor prognosis. Advances in HER2-targeted therapies, such as monoclonal antibodies (trastuzumab, pertuzumab), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs), have significantly improved treatment outcomes in this subtype. Neoadjuvant therapy, administered before surgery, has become a cornerstone in managing HER2-positive breast cancer by improving pathological complete response (pCR) rates and survival outcomes. This review provides a comprehensive analysis of recent advancements in HER2-targeted neoadjuvant therapies, highlighting the mechanisms of action, clinical efficacy, and synergistic effects when combined with chemotherapy. Key challenges, such as treatment-related toxicities, and the potential for personalized treatment strategies based on biomarkers like tumor-infiltrating lymphocytes (TILs) and HER2-enriched subtypes, are discussed. Future directions emphasize optimizing treatment regimens to enhance efficacy while minimizing adverse effects, with novel agents such as trastuzumab deruxtecan (T-DXd) showing promise for expanding the therapeutic landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen University, Guangzhou, China.
- Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
- The Second Clinical Medical College, Nanchang University, Nanchang, China.
- Department of Medical Sciences, Fuzhou Medical College, Nanchang University, Fuzhou, China.
- The First Clinical Medical College, Nanchang University, Nanchang, China.
- School of Clinical Medicine, Nanchang Medical College, Nanchang, China.
ORCID-Profile: Haizhu Chen
Förderung
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Shang, A., Xiong, Y., Li, M., Tang, W., Wan, K., Deng, Z., Mao, X., & Chen, H. (2026). Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment for HER2-Positive Breast Cancer. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338261446455
Vancouver
Shang A, Xiong Y, Li M, Tang W, Wan K, Deng Z, et al. Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment for HER2-Positive Breast Cancer. Technology in Cancer Research & Treatment. 2026. doi:10.1177/15330338261446455
BibTeX
@article{Shang2026,
author = {Shang, Anqi and Xiong, Yunjing and Li, Min and Tang, Wanxin and Wan, Keyu and Deng, Zekang and Mao, Xianxian and Chen, Haizhu},
title = {Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment for HER2-Positive Breast Cancer},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
doi = {10.1177/15330338261446455}
}
EUVIMED